Develop cgmp technology for crispr/CAS genome editing of cells for use in cell-based immunotherapy for cancer
Ended Awarded Last action
- Contract number
- 75N91020F00017
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,033,134
Award facts
- Contract value 100% obligated
- $4,033,134.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $4,033,134 |
About this award
This is a federal contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. The $4,033,134.00 contract is a cost-plus-fixed-fee delivery order to develop cGMP (current Good Manufacturing Practice) technology for CRISPR/Cas genome editing of cells for use in cell-based immunotherapy for cancer. There is no set-aside designation for this award.
Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. and serves as an FFRDC (Federally Funded Research and Development Center) contractor for the NCI, providing a range of biomedical research and facilities support services. This contract contributes to advancing cancer research and cell-based therapeutic development under the NCI's mission. The contract involves capital equipment purchases from subcontractors Franklin Young International, Inc. (a Service-Disabled Veteran-Owned Small Business) and Government Scientific Source Inc. to support the technical work.
Quick answers
Who was awarded contract 75N91020F00017?
75N91020F00017 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2020.
How much is contract 75N91020F00017 worth?
The government has obligated $4,033,134 on 75N91020F00017.
Is contract 75N91020F00017 an order under another contract?
Yes. 75N91020F00017 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91020F00017 competed?
The extent of competition for 75N91020F00017 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award